Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1989 1
1990 1
1992 3
1993 1
1994 1
1995 13
1996 1
1997 5
1998 3
1999 2
2000 3
2001 7
2002 3
2003 4
2004 3
2005 5
2006 8
2007 6
2008 2
2009 7
2010 9
2011 6
2012 3
2013 1
2014 2
2015 2
2016 6
2017 12
2018 10
2019 14
2020 14
2021 20
2022 18
2023 18
2024 16
2025 17
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. Among authors: even c. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Bourhis J, Aupérin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Bourhis J, et al. Among authors: even c. Lancet. 2026 Jan 24;407(10526):363-374. doi: 10.1016/S0140-6736(25)01850-1. Epub 2025 Dec 22. Lancet. 2026. PMID: 41448222 Clinical Trial.
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S. Rached L, et al. Among authors: even c. Cancer Treat Rev. 2024 Jun;127:102751. doi: 10.1016/j.ctrv.2024.102751. Epub 2024 May 4. Cancer Treat Rev. 2024. PMID: 38729086 Free article. Review.
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up.
van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A, Baujat B, Locati LD, Jensen AD, Smeele L, Hardillo J, Martineau VC, Trama A, Kinloch E, Even C, Machiels JP; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. van Herpen C, et al. Among authors: even c. ESMO Open. 2022 Dec;7(6):100602. doi: 10.1016/j.esmoop.2022.100602. Epub 2022 Nov 2. ESMO Open. 2022. PMID: 36567082 Free PMC article.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: even c. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. Among authors: even c. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Ferris RL, et al. Among authors: even c. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17. Oral Oncol. 2018. PMID: 29884413 Free PMC article. Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Among authors: even c. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies.
Colevas AD, Talebi Z, Winters E, Even C, Lee VH, Gillison ML, Khan SA, Lu R, Pinsky BA, Soldan SS, Vladmirova O, Lieberman PM, Messick TE. Colevas AD, et al. Among authors: even c. Clin Cancer Res. 2025 Mar 3;31(5):815-823. doi: 10.1158/1078-0432.CCR-24-2814. Clin Cancer Res. 2025. PMID: 39831818 Free PMC article. Clinical Trial.
225 results